Planned hires take sting out of Genzyme layoffs

As if it intends to use regular antithetical announcements as a way of keeping Boston media outlets off-balance, Genzyme is now accelerating the hiring of manufacturing and quality control workers in Massachusetts. Its plans call for the hiring of 500 to 600 production workers in Massachusetts, beginning last July and extending to the end of 2011, reports the Boston Globe.

The news follows a Boston Herald report from last week saying that the biopharma giant will shed 1,000 jobs worldwide. We had reported a few days earlier on another Globe report, this one speculating that the specialized nature of Genzyme's drugs may be a factor in minimizing manufacturing layoffs.

"The point is to be more efficient and more effective,'' says Ann Merrifield, Genzyme's senior VP for business excellence, in the current Globe report. "As we redesign our operations and processes, there are opportunities to reinvest in higher value operations.''

It's all to show that Genzyme is executing on a five-point plan it unveiled last spring, says Moody's senior VP Michael Levesque, in the article. That plan was created to resolve a long list of manufacturing problems and calm activist shareholders.

- see the article

Webinar

Using AI and RWD to Uncover Rare Disease Insights, Accelerate Commercialization and Improve Patient Outcomes

Wednesday, March 24 | 2pm ET / 11am PT

Learn how IPM.ai transformed real world data into real world insights to assist Audentes in their development of AT132 for the treatment of XLMTM. The session reviews how IPM.ia and Audentes collaborated to uncover the XLMTM patient population.